EMEkaterina Vladimirovna Makhnovich

Ekaterina Vladimirovna Makhnovich

*This is an algorithmically generated author record based on publicly available information.

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ekaterina Vladimirovna Makhnovich has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Modifiable risk factors for Alzheimer’s disease

    by E.V. Makhnovich, E.A. Kovalenko, N.A. Osinovskaya, A.I. Shutikova, I.I. Kovaleva, A.N. Bogolepova

    Alzheimer’s disease is a prominent medical and social challenge of our time and stands as the leading cause of dementia, resulting in significant disability for those affected. Since no etiotropic therapy is available, prioritizing primary and secondary prevention through the management of the key factors contributing to the development of Alzheimer’s disease has become imperative for the medical community. In recent years, there has been an increasing focus on investigating modifiable risk factors, which may have the potential to prevent up to 45% of dementia cases over a person’s lifetime. This article provides an overview of 14 risk factors associated with dementia and examines the pathogenic mechanisms that connect these factors to the onset of Alzheimer’s disease.

  • Experience in the implementation of a comprehensive non-pharmacological therapeutic program at the Center for Cognitive and Psycho-Emotional Health

    by V.V. Belousov, Y.S. Gureeva, R.T. Tairova, A.N. Bogolepova, E.A. Gileva, E.A. Kovalenko, E.V. Makhnovich

    Objective. To analyze the outcomes of a complex non-pharmacological treatment regimen administered to patients at the daytime hospital (DH) of the Center for Cognitive and Psycho-Emotional Health (CCPH) and to evaluate the changes in the cognitive and psycho-emotional state of the patients. Material and methods. The study included 103 patients attending the CCPH DH, with a mean age of 46.98±14.32 years; 76.7% were female. Participants were categorized into three distinct groups: Group 1 with predominantly cognitive impairments (CIs), Group 2 with predominantly psycho-emotional disorders, and Group 3 with sleep disorders. Cognitive and psycho-emotional statuses were assessed using widely accepted tests and assessment scales. Each participant underwent a tailored five-day course of non-pharmacological therapy, which integrated cognitive training, biofeedback-based electroencephalography training, physical therapy, and neurostimulation techniques. Treatment outcomes were assessed after the intervention. Results. Following the therapeutic intervention, 91.26% of participants demonstrated clinical improvement, with the greatest improvement observed in Group 2 (96.6%). No deterioration in clinical status was noted among any of the patients, thereby affirming the safety of the therapeutic interventions. Neuropsychological test results indicated a statistically significant improvement across all three groups (p<0.05), reflected in enhanced cognitive metrics and a reduction in anxiety and depressive symptoms among patients with pre-dementia CIs, anxiety disorders, and chronic insomnia. While a tendency towards improvement was noted in patients with severe ICs, the changes did not reach statistical significance, particularly in patients with isolated depressive disorders, potentially due to the limited sample size. Moreover, patients within Group 3 showed improvements in sleep during the therapy. Conclusions. The findings suggest that a five-day non-pharmacological intervention with an integrated approach represents an effective and safe method for the maintenance and enhancement of cognitive and psycho-emotional health.

  • Current perspectives on non-pharmacological approaches to cognitive impairment

    by E.A. Gileva, E.A. Kovalenko, E.V. Makhnovich, N.A. Osinovskaya, A.N. Bogolepova

    Cognitive impairment (CI) is increasingly recognized as a significant public health issue. Despite extensive research into its causes, mechanisms, and risk factors, along with advancements in pharmacological treatments for associated conditions, preventing or slowing the progression of cognitive decline often cannot be achieved through medication alone. Consequently, non-pharmacological strategies are also employed to support cognitive health in patients with cognitive disorders. This literature review explores the most effective non-drug therapies for cognitive impairment, as well as potential combinations of these approaches.

  • Cognitive health of Moscow residents 55 years and older: Epidemiological data

    by V.V. Belousov, Y.S. Gureeva, R.T. Tairova, A.N. Bogolepova, E.A. Kovalenko, E.V. Makhnovich, E.V. Erokhina

    Objective. To study the prevalence of cognitive impairment (CI) in persons aged ≥55 years living in the city of Moscow, based on the data from the program for the preservation of cognitive skills and psycho-emotional health implemented at the Moscow Longevity Centers. Material and methods. The study used a depersonalized electronic database containing the results of the specialized computer training course, «Neurotraining of Cognitive Skills», which is part of the program implemented at the Moscow Longevity Centers. The final analysis included 33.164 subjects aged 55 and older who completed a Cognitive Assessment Questionnaire during the course, including both data on the functioning of individual cognitive domains (memory, attention, and reasoning) and an integrative assessment of CIs. The median age was 67.0 [62.0; 73.0] years. In this group, females accounted for 85.35%. The majority of program participants had higher education (74.62%) and were right-handed (97.61%). Results. Evaluation of individual cognitive domains using the Questionnaire showed that most participants (75.29%) had decreased attention, varying in severity. However, evaluation of individual responses to the Questionnaire (86.85%) showed that most participants reported memory impairment as their main complaint. According to the data of the integrative assessment of the CI prevalence according to the Questionnaire, the following results were obtained: 49.59% of the subjects had possible moderate cognitive impairment and 9.09% of the subjects had possible severe cognitive impairment. The older the program participants were, the more pronounced the decrease in memory, attention, reasoning, and the integrative CI assessment was observed (r=0.038, r=0.035, r=0.096, and r=0.051, p<0.01, respectively). Conclusion. The results of our data analysis complemented the epidemiological statistics on the prevalence of cognitive impairment among persons aged 55 and older in the city of Moscow. The results indicate the need for cognitive screening in persons 55 years and older to timely detect CI, determine the appropriate route, and administer the necessary therapy, including non-drug methods for CI correction.

  • Results of the program to preserve cognitive skills and psycho-emotional health in Moscow Longevity Centers

    by V.V. Belousov, Yu.S. Gureeva, R.T. Tairova, A.N. Bogolepova, G.E. Ivanova, E.A. Kovalenko, E.V. Makhnovich, E.V. Erokhina, M.G. Khlyustova

    Objective. To analyze the effects of computer cognitive training (CT) and biofeedback training (BFT) based on electroencephalography (EEG) in persons aged 55 and older, using the program’s electronic databases on the preservation of cognitive skills and psycho-emotional health at the Moscow Longevity Centers. Material and methods. Electronic databases were analyzed based on the results of two specialized courses, «Neurotraining of Cognitive Skills» (Group 1) and «Neurocorrection of Psychoemotional State» (Group 2), as part of the program at the Moscow Longevity Centers. Group 1 included 13.379 subjects (median age 72 [69.0; 77.0] years), Group 2 included 11 697 subjects (66 [63.0; 73.0] years). Group 1 used computer CT with an assessment of the following indicators of cognitive functions based on the integral score: individual reasoning performance (IRP), memory, attention, and reasoning. For Group 2, EEG-based BFT with neurophysiological parameter assessment was used. All indicators and parameters were followed up on. The effectiveness of the methods was assessed after 10 sessions. Results. In Group 1, a statistically significant increase in all cognitive function indicators by both 5 and 10 CT sessions (p<0.001) was observed. Moreover, the more sessions were completed, the more pronounced the effect was (p90%). In Group 2, the data analysis also showed a statistically significant improvement in neurophysiological parameters after the EEG-based BFT in the vast majority of subjects (89.3%). Conclusion. The results indicate a high potential for the studied non-drug methods to support cognitive and psycho-emotional health. Therefore, these methods should be recommended for wide use in preventive programs for persons 55 years and older.

  • A new look at blood biomarkers in Alzheimer’s patients

    by A.N. Bogolepova, E.A. Kovalenko, E.A. Gileva, E.V. Makhnovich, A.D. Gasilova, D.I. Skvortsov

    Alzheimer’s disease (AD), as one of the leading causes of dementia in the world, is a neurodegenerative disease with a long pre-symptomatic period and the development of slowly progressive cognitive impairment. The rising number of patients diagnosed with AD and the socio-economic impacts of this condition necessitate the proactive identification and implementation of effective disease control methods in clinical practice. One of the key areas is the improvement of methods for the early diagnosis of AD, thus enabling therapeutic intervention at pre-dementia stages and further prevention of irreversible progressive degeneration of neuronal structures. Diagnosis of AD is based on a combination of clinical and neuroimaging data, as well as analysis of the spectrum of biological markers in cerebrospinal fluid. However, the use of this laboratory method in clinical practice is limited due to the low accessibility and invasive nature of the sampling procedure. Therefore, the study of blood biomarkers is a promising area for the diagnosis of the disease. The presented literature review addresses data on traditional blood biomarkers of AD diagnosis from the modern point of view for the pathogenesis of AD, and also summarizes the results of studies conducted to date on less studied blood biomarkers in AD, which have possible diagnostic potential for the development of cost-effective and affordable biomarkers for preclinical diagnosis.

  • Epileptic seizures in patients with Alzheimer’s disease

    by S.G. Burd, A.N. Bogolepova, A.V. Lebedeva, Yu.V. Rubleva, E.A. Kovalenko, E.V. Makhnovich, N.A. Osinovskaya, E.A. Gileva, N.V. Pantina, I.I. Kovaleva, et al.

    Neurodegenerative diseases are one of the leading causes of epileptic seizures with onset in later life. Particular attention is paid to Alzheimer’s disease (AD), as a disease that accounts for up to 70% of cases of all types of dementia, and, according to the literature, shares genetic and pathophysiological mechanisms with epilepsy. This paper reviews the literature on the prevalence of epilepsy in AD patients. The reasons for the widely varying data (ranging from 0.5 to 64%) depending on the selected population, the reliability of the established diagnosis, the form and genetic characteristics of the disease, as well as the examination methods used, are considered. The main risk factors for the development of AD and epilepsy, semiotics and features of seizures in patients with AD, as well as approaches to the treatment of such patients, are also covered.

  • Open Access

    Diagnostic significance of subclinical epileptiform activity in patients with alzheimer’s disease

    by S. G. Burd, A. N. Bogolepova, A. V. Lebedeva, Yu. V. Rubleva, E. A. Kovalenko, E. V. Makhnovich, N. A. Osinovskaya, E. A. Gileva, N. V. Pantina, I. I. Kovaleva

    Introduction. The high prevalence and significant disability of patients with Alzheimer’s disease (AD) necessitate the search for new markers of disease progression and novel treatment approaches. Recent evidence is increasingly attracting the research attention to the value of electroencephalography (EEG) in detecting epileptiform activity in this patient population. Objective . Detection of the frequency of epileptiform activity in patients with AD and evaluation of its clinical and diagnostic significance. Discussion . EEG, in particular, prolonged sleep-deprived EEG, is capable of detecting subclinical epileptiform activity, which is associated with more severe cognitive impairments and contributes to disease progression. This review examines research data on the prevalence and clinical significance of subclinical epileptiform activity in AD patients without an epilepsy diagnosis. It also highlights key pathophysiological mechanisms linking epileptiform activity to the progression of cognitive decline in AD. Furthermore, it addresses the rationale for prescribing specific antiepileptic therapy upon detection of subclinical epileptiform activity. Conclusions. The high clinical significance of performing electroencephalography and detecting epileptiform activity in patients with Alzheimer’s disease, due to its potential negative impact on the progression of cognitive impairments and increased risks of developing epileptic seizures, has been demonstrated.

  • Open Access

    Differential diagnosis features of rapidly progressive Alzheimer’s disease

    by M. Yu. Martynov, A. N. Bogolepova, E. V. Makhnovich, E. A. Kovalenko

    Особенности дифференциального диагноза быстропрогрессирующей болезни Альцгеймера

  • Open Access

    Assessment of biomarkers in biological fluids and neuroimaging changes in patients with Alzheimer’s disease and glaucoma

    by A. N. Bogolepova, E. V. Makhnovich, E. A. Kovalenko, N. A. Osinovskaya, M. M. Beregov, O. V. Lyang

    Оценка биомаркеров в биологических жидкостях и нейровизуализационных изменений у пациентов с болезнью Альцгеймера и глаукомой